Dr. Rathjen, who is a member of the board of directors and has served as executive chair since December 10, 2018, replaces Dr. Mark Day, who has left the company, effective immediately.
The board would like to thank Dr. Mark Day for his contributions to the company over the past few years and wish him well in his future endeavours.
Bioasis also said it has recently granted stock options to acquire a total of 1.616m common shares at exercise prices ranging from USD 0.445 – USD 0.55 per share to executives of the company, with the exception of Dr. Rathjen. 95,000 of these options vest over a period of one year and the balance vest over a period of five years.
All of the options have a five year term and are governed by the terms of the company's stock option plan.
Bioasis Technologies is a biopharmaceutical company developing the xB3 TM platform, a proprietary technology for the delivery of therapeutics across the blood-brain barrier and the treatment of CNS disorders in areas of high unmet medical need.
The delivery of therapeutics across the BBB represents the final frontier in treating neurological disorders. Bioasis' internal pipeline programs are focused on treatments for orphan indications, including certain brain cancers, and rare diseases, including Gaucher's Disease Type II.
The company maintains headquarters in Guilford, Connecticut.
Bioforum, The Data Masters names new President
VolitionRx names new Chief Medical Officer
Quotient Sciences announces new appointments
Syndax Pharmaceuticals names new chief commercial officer
Everest Medicines names new chief medical officer and chief product officer
D3 Bio names new independent board member
Rigel Pharmaceuticals names new executive vice president and chief medical officer
Telix Pharmaceuticals names new group chief operating officer